Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Diphtheria Market Size Changed, over the years?

In recent times, the market size of diphtheria has witnessed robust growth. It’s expected to escalate from $8.91 billion in 2024 and reach up to $9.51 billion in the following year with a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be credited to the development of vaccines, immunization drives, increased cognizance, and improved healthcare infrastructure.

How Much Will the Diphtheria Market Be Worth in 2029?

In the coming years, robust expansion is anticipated in the diphtheria market, projected to reach $12.35 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. This promising growth during the predicted period can be attributed to factors such as emerging disease outbreaks, enhanced booster vaccination schemes, worldwide travel and migration, and public health readiness. Noteworthy trends expected during this period include the use of combination vaccines, the application of telemedicine for vaccination purposes, vaccine equity initiatives, and collaborations between public and private sectors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13016&type=smp

Which is the Largest Company in the Diphtheria Market?

Major companies operating in the diphtheria market are Pfizer Inc., Johnson & Johnson Co, Roche Holding AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Serum Institute of India, Novavax Inc., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Bharat Biotech International Limited, CureVac AG, Inovio Pharmaceuticals Inc., The Native Antigen Company.

What Are the Main Market Drivers in the Diphtheria Industry?

The increasing instances of bacterial infections are anticipated to drive the diphtheria market’s growth. Bacterial infections, which are illnesses or conditions caused by bacterial growth or bacterial-produced toxins invading the body, are becoming more common. Diphtheria, a severe infection initiated by bacteria strains that weaken the immune system and encourage the growth of Corynebacterium diphtheria, is a prime example. As reported by GOV.UK, a UK government website, in September 2024, NHS acute trusts in England reported 38,757 E. coli bacteremia cases in the 2022-2023 fiscal year, with 7,881 cases (20.3%) categorized as hospital-onset infections. Hence, the escalating prevalence of bacterial infections is expected to push forward the diphtheria market.

Diphtheria Market Driver: Rising Immunization Programs Bolstering Diphtheria Market Growth

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13016&type=smp

How Is the Diphtheria Market Segments Structured?

The diphtheria market covered in this report is segmented –

1) By Type: Diphtheria, Skin Diphtheria, Other Types

2) By Diagnosis: Physical Examination, Throat Culture, Other Diagnosis

3) By Treatment: Antibiotics, Antitoxin, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Diphtheria: Respiratory Diphtheria, Non-respiratory Diphtheria

2) By Skin Diphtheria: Cutaneous Diphtheria

3) By Other Types: Diphtheritic Myocarditis, Diphtheritic Neuritis

What Strategic Trends Are Transforming the Diphtheria Market?

Leading firms in the diphtheria market are focusing on the development of novel drugs and securing necessary approvals to maintain their market standing. For instance, GlaxoSmithKline PLC, a pharmaceutical and biotechnology entity based in the UK, announced in October 2022 that BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, adsorbed; Tdap) had received approval from the US Food and Drug Administration (FDA). This vaccine is intended for immunization during the third month of pregnancy to aid in the prevention of pertussis (whooping cough) in babies under two months old. The Tdap vaccine, when administered during pregnancy, provides the utmost protection from whooping cough to newborns in their initial months. This mechanism works by the transfer of protective antibodies from the mother to the baby when the mother is immunized during pregnancy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/diphtheria-global-market-report

Which Global Regions Offer the Highest Growth in the Diphtheria Market?

Asia-Pacific was the largest region in the diphtheria market in 2024. The regions covered in diphtheria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13016

This Report Delivers Insight On:

1. How big is the diphtheria market, and how is it changing globally?

2. Who are the major companies in the diphtheria market, and how are they performing?

3. What are the key opportunities and risks in the diphtheria market right now?

4. Which products or customer segments are growing the most in the diphtheria market?

5. What factors are helping or slowing down the growth of the diphtheria market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model